Share ownership Laboratorios Farmaceuticos Rovi, S.A. OTC Markets
Stocks
LABFF
ES0157261019
Pharmaceuticals
|
Market Closed -
OTC Markets
18:45:10 20/10/2023 +04
|
5-day change | 1st Jan Change | ||
| 52.00 USD | -3.93% |
|
-22.58% | -21.05% |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Share class: Laboratorios Farmaceuticos Rovi, S.A.
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 51,235,762 | 16,208,105 ( 31.63 %) | 92,764 ( 0.1811 %) | 31.63 % |
Major shareholders: Laboratorios Farmaceuticos Rovi, S.A.
| Name | Stocks | % | Valuation |
|---|---|---|---|
Norbel Inversiones SL
58.19
%
| 29,812,040 | 58.19 % | 2 008 M $ |
Indumenta Pueri SL
10.01
%
| 5,126,303 | 10.01 % | 345 M $ |
Santander Private Banking Gestion SA SGIIC
1.14
%
| 584,258 | 1.14 % | 39 M $ |
Invesco Asset Management Ltd.
0.959
%
| 491,351 | 0.959 % | 33 M $ |
Shareholder Value Management AG
0.8632
%
| 442,243 | 0.8632 % | 30 M $ |
Muza Gestion de Activos SGIIC SA
0.6968
%
| 356,992 | 0.6968 % | 24 M $ |
BN & Partners Capital AG
0.6914
%
| 354,236 | 0.6914 % | 24 M $ |
Financière de l'Échiquier SA
0.5994
%
| 307,085 | 0.5994 % | 21 M $ |
Bestinver Gestión SA SGIIC
0.5136
%
| 263,160 | 0.5136 % | 18 M $ |
Bankinter Gestión de Activos SA SGIIC
0.4085
%
| 209,297 | 0.4085 % | 14 M $ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
░░░░░░░░░░░░░░░░░ | ░ ░░░ | ░░░░% | ░░ |
Breakdown by shareholder type
| Others | 68.19% |
| Institutional | 9.77% |
| Laboratorios Farmaceúticos Rovi SA | 0.17% |
| Unknown | 21.87% |
Based on 1000 largest holdings
Geographical origin of shareholders
Spain | 73.74% |
Germany | 1.74% |
United Kingdom | 1.11% |
France | 0.79% |
Luxembourg | 0.2% |
Netherlands | 0.18% |
Italy | 0.17% |
Finland | 0.16% |
United States | 0.01% |
Belgium | 0.01% |
Malta | 0.01% |
Switzerland | 0.01% |
Based on 1000 largest holdings
Employees
2,470
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
















